Inotiv (NASDAQ:NOTV), formerly known as Bioanalytical Systems, Inc. (NASDAQ: NOTV), is a global contract research organization (CRO) specializing in preclinical drug discovery, development and testing services. The company partners with pharmaceutical, biotech and medical device companies to advance candidate molecules through early‐stage research and safety assessment. Inotiv’s integrated platform spans in vivo and in vitro pharmacology, drug metabolism and pharmacokinetics (DMPK), toxicology, pathology and bioanalysis.
The company’s core service offerings include discovery pharmacology, safety assessment toxicology, pathology, bioanalysis and regulatory support. Inotiv’s facilities are designed to meet stringent regulatory standards and accommodate a wide range of study types, from small molecule and biologic evaluation to specialty services addressing ophthalmology, neuroscience and cardiovascular indications. With laboratory locations in the United States, Europe and Asia Pacific, Inotiv serves a diverse client base seeking scalable, GLP‐compliant research solutions.
Inotiv traces its roots to the founding of Bioanalytical Systems, Inc. in the early 1980s and formally adopted the Inotiv name in 2020 to reflect its broadening suite of scientific services. Headquartered in West Lafayette, Indiana, the company has grown through strategic investments in technology platforms and site expansions. Inotiv is led by a management team with deep expertise in biopharmaceutical research and CRO operations, positioning the company to support clients from target identification through IND filing and beyond.
